The efficacies of non-bismuth containing quadruple therapies in the treatment of first-line anti-Helicobacter pylori across 4-year time interval with changing antibiotics resistance

Huang, Tsui-Chin; Yang, Shih‐Cheng; Tai, Wei‐Chen; Liang, Chih‐Ming; Kuo, Chien-Lin; Yao, Chih‐Chien; Wu, Cheng‐Kun; Kuo, Yuan-Hung; Chou, Yeh‐Pin; Lee, Chen‐Hsiang; Wu, Keng‐Liang; Chuah, Seng‐Kee

doi:10.1016/j.bj.2020.11.012

Cited by 7 publications

(3 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 28 The prevalence rates of primary antibiotic resistance to metronidazole, tetracycline, and clarithromycin are about 35%, 0%, and 20% in Taiwan, respectively. 9 , 29 , 30 It is justifiable to suggest 10-day bismuth quadruple therapy for first-line H. pylori eradication because it achieves adequate efficacy in geographic regions without high-level metronidazole resistance and its results are similar to estimated results. 22 Nevertheless, the efficacy of 10-day standard bismuth quadruple therapy may not be applicable to geographic regions where the prevalence of metronidazole-resistant H. pylori is >40%.…”

Section: Discussionmentioning

confidence: 97%

10-Day versus 14-day bismuth quadruple therapy for first-line eradication of Helicobacter pylori infection: a randomised, open-label, non-inferiority trial

Yang,

Chen,

Chiang

et al. 2024

eClinicalMedicine

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 97%

10-Day versus 14-day bismuth quadruple therapy for first-line eradication of Helicobacter pylori infection: a randomised, open-label, non-inferiority trial

Yang,

Chen,

Chiang

et al. 2024

eClinicalMedicine

View full text Add to dashboard Cite

“…It has the highest eradication rates of about 90%, even in areas of high metronidazole and clarithromycin resistance [7]. However, the success rate of a 7-day concomitant therapy has decreased due to changes in clarithromycin resistance patterns [13].…”

Section: Non-bismuth-based Quadruple Therapymentioning

confidence: 99%

Current Perspective on the Treatment of Helicobacter pylori Infection

Taufiq,

Taufiq

2024

Tertiary Care - Medical, Psychosocial, and Environmental Aspects

View full text Add to dashboard Cite

Helicobacter pylori (H. pylori) is a gram-negative aerobic bacteria that infects humans and is responsible for causing more than 80% of cases of chronic gastritis, peptic ulcer disease, and non-cardia gastric cancer. Both peptic ulcer disease and gastric cancer lead to 1 million deaths annually. H. pylori is a pathogen responsible for these conditions, highlighting the importance of accurate diagnosis and eradication. Various invasive and non-invasive methods are available to diagnose with varying sensitivity and specificity. Invasive methods include endoscopy, culture, histology, rapid urease test, and molecular tests such as PCR. Non-invasive tests include serology, urea breath test, and stool antigen tests. However, there is growing concern about the increasing resistance of H. pylori to commonly available treatments. The lack of availability of invasive and non-invasive procedures to detect H. pylori worldwide, particularly in developing countries, are important concerns that need to be addressed in the future. Hence in the future, more emphasis should be placed on the development of an effective vaccine against H. pylori.

show abstract

“…analyzed the efficacy of concomitant therapy in 246 patients in a Taiwanese hospital during a period of increasing clarithromycin resistance in Taiwan. The success rate of the treatment decreased with changes in antibiotic resistance [ 47 ].…”

Section: Also In This Issuementioning

confidence: 99%

The best protection is early detection

Kattner¹

2021

Biomedical Journal

View full text Add to dashboard Cite

The efficacies of non-bismuth containing quadruple therapies in the treatment of first-line anti-Helicobacter pylori across 4-year time interval with changing antibiotics resistance

Cited by 7 publications

References 31 publications

10-Day versus 14-day bismuth quadruple therapy for first-line eradication of Helicobacter pylori infection: a randomised, open-label, non-inferiority trial

10-Day versus 14-day bismuth quadruple therapy for first-line eradication of Helicobacter pylori infection: a randomised, open-label, non-inferiority trial

Current Perspective on the Treatment of Helicobacter pylori Infection

The best protection is early detection

Contact Info

Product

Resources

About